Neurocrine Biosciences Inc (NBIX): Next-Year EPS Estimate 25.10%
As of 2026-05-06, Neurocrine Biosciences Inc (NBIX) has a next-year EPS growth estimate of 25.10%.
On 2026-05-06, analyst consensus for NBIX's next-year EPS growth shifted from 37.33% to 25.10% — a negative change of 12.23 percentage points. Current-year growth is projected at 58.83%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- EPS growth next year
- 25.10%
- EPS growth this year
- 58.83%
- EPS next quarter (est)
- $1.57
- Last price
- $147.02
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-05-06 | 25.10% | 58.83% | $1.57 | $147.02 |
| 2026-05-05 | 37.33% | 30.74% | $1.22 | $135.06 |
| 2026-05-04 | 37.33% | 30.74% | $1.22 | $134.07 |
| 2026-05-03 | 37.33% | 30.74% | $1.22 | $131.78 |
| 2026-04-30 | 37.00% | 33.10% | $1.22 | $131.67 |
| 2026-04-29 | 37.00% | 33.10% | $1.22 | $131.23 |
| 2026-04-28 | 37.00% | 33.10% | $1.22 | $128.12 |
| 2026-04-27 | 37.00% | 33.10% | $1.22 | $128.04 |
| 2026-04-26 | 37.00% | 33.10% | $1.22 | $127.68 |
| 2026-04-24 | 37.00% | 33.10% | $1.22 | $127.68 |
| 2026-04-23 | 35.50% | 31.51% | $1.21 | $130.19 |
| 2026-04-22 | 35.50% | 31.51% | $1.21 | $131.18 |
| 2026-04-21 | 35.71% | 30.98% | $1.18 | $130.22 |
| 2026-04-20 | 35.55% | 31.15% | $1.17 | $131.59 |
| 2026-04-19 | 35.55% | 31.15% | $1.17 | $133.25 |
| 2026-04-16 | 36.29% | 31.63% | $1.17 | $128.41 |
| 2026-04-15 | 36.29% | 31.63% | $1.17 | $131.44 |
| 2026-04-14 | 36.29% | 31.63% | $1.16 | $130.81 |
| 2026-04-13 | 36.68% | 31.27% | $1.16 | $126.32 |
| 2026-04-12 | 36.11% | 30.75% | $1.17 | $128.89 |
| 2026-04-10 | 36.11% | 30.75% | $1.19 | $129.29 |
| 2026-04-09 | 34.09% | 31.76% | $1.19 | $131.64 |
| 2026-04-08 | 34.09% | N/A | $1.19 | $133.15 |
| 2026-04-07 | 34.09% | N/A | $1.19 | $130.90 |
| 2026-04-06 | 34.09% | N/A | $1.19 | $130.90 |
| 2026-04-05 | 30.06% | N/A | $1.15 | $131.60 |
| 2026-04-03 | 34.09% | N/A | $1.19 | $130.90 |
| 2026-04-02 | 34.09% | N/A | $1.19 | $130.90 |
| 2026-04-01 | 34.09% | N/A | $1.19 | $130.90 |
| 2026-04-01 | 30.06% | N/A | N/A | $131.74 |
Recent News
- Oil Climbs, Stocks Whipsaw After Trumps Warning: Markets WrapBloomberg
- Neurocrine Agrees $2.9 Billion Soleno Deal At 34% PremiumGuruFocus.com
- Stock Bounce Fades, Oil Climbs on Trumps Remarks: Markets WrapBloomberg
- Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B dealProactive
- SLNO Jumps As Deal Buzz Lifts StocksGuruFocus.com
- Neurocrine to Buy Soleno for $2.9 BillionThe Wall Street Journal
- This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal.Barrons.com
- Neurocrine wants to develop new obesity drugs. It's reportedly nearing an acquisition to accelerate that move.MarketWatch
- Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease PortfolioPR Newswire
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Neurocrine Biosciences Inc's next-year EPS growth estimate?▾
As of 2026-05-06, Neurocrine Biosciences Inc (NBIX) has a next-year EPS growth estimate of 25.10%, based on analyst consensus.
When was the latest EPS estimate revision for NBIX?▾
The most recent revision occurred on 2026-05-06, when analysts adjusted the next-year EPS growth estimate from 37.33% to 25.10%.
What sector and industry does Neurocrine Biosciences Inc belong to?▾
Neurocrine Biosciences Inc operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. NBIX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Neurocrine Biosciences Inc (NBIX) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports